Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Inclusion Criteria: * Presence of BRAF V600E mutation in tumor tissue * Histologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLC * At least one measurable lesion as defined by RECIST v1.1 * Patients must have progressed during or after at least one previous systemic, anti-cancer treatment for locally advanced or metastatic NSCLC. * Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status 0-2 Exclusion Criteria: * Patients with symptomatic Central Nervous System (CNS) metastases * History of leptomeningeal metastases * Prior therapy with a BRAF inhibitor * Patients taking prohibited medication listed in the protocol * Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years. * Impaired cardiovascular function or clinically significant cardiovascular diseases * Pregnant or lactating women or woman of childbearing potential